ArticleStroke (Hoboken, N.J.)2025
Influence of Comorbidity on Endovascular Thrombectomy Outcomes for Medium-Vessel Occlusion Stroke: A Nationwide Prospective Observational Study.
Article in Stroke (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comorbidity burden may affect the outcome following endovascular thrombectomy (EVT) for medium-vessel occlusions. Since patients with high comorbidity burden are likely to be underrepresented in trials on EVT for medium-vessel occlusions, observational data are needed to assess the benefit of EVT for these patients. Methods: We conducted an observational study on all prestroke independent patients treated with EVT for medium-vessel occlusions in the MCA territory in Sweden from 2015 to 2021. Comorbidity burden was weighted according to the Charlson Comorbidity Index (CCI) and categorized into no comorbidity (CCI 0); moderate to severe comorbidity (CCI 1-2); and very severe comorbidity (CCI ≥3). The primary outcome was a favorable outcome (modified Rankin Scale 0-2) at 90 days after EVT in relation to comorbidity burden. Excellent outcome (modified Rankin Scale 0-1) and symptomatic intracranial hemorrhage were secondary outcomes. In an exploratory analysis, we compared outcomes on the basis of successful recanalization (modified Thrombolysis in Cerebral Infarction 2b-3). Results: Among 983 patients, 37% had no comorbidity (CCI 0), 35% had moderate to severe comorbidity burden (CCI 1-2), and 27% had a very severe comorbidity burden (CCI ≥3). Favorable and excellent outcomes were most frequent in the CCI 0 group (61% and 25%) and least frequent in the CCI ≥3 group (29% and 13%) ( Conclusion: Moderate to very severe comorbidity burden is common among EVT-treated patients with medium-vessel occlusions in routine clinical practice and is associated with worse prognosis compared with patients with no comorbidity. Our results highlight the importance of achieving successful recanalization, which appears highly beneficial across all comorbidity levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.